Evidence map›Paper›PMID 35535072›Full record

ArticleJournal of clinical and experimental hepatology

Prophylactic Perioperative Terlipressin Therapy for Preventing Acute Kidney Injury in Living Donor Liver Transplant Recipients: A Systematic Review and Meta-Analysis.

Anand V Kulkarni, Karan Kumar, Roberto Candia, Juan P Arab, Harsh V Tevethia, Madhumita Premkumar, Mithun Sharma, Balachandandran Menon, Guduru V Rao, Nageshwar D Reddy and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Anand V KulkarniDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Karan KumarDepartment of Hepatology, Pacific Institute of Medical Sciences, Udaipur, India.
Roberto CandiaDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Juan P ArabDepartamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Harsh V TevethiaDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Madhumita PremkumarDepartment of Hepatology, PGIMER, Chandigarh, India.
Mithun SharmaDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Balachandandran MenonDepartment of Hepatobiliary Surgery and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India.
Guduru V RaoDepartment of Hepatobiliary Surgery and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India.
Nageshwar D ReddyDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Nagaraja P RaoDepartment of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Asian Institute of Gastroenterology · INPontificia Universidad Católica de Chile · CLPacific Dental College and Hospital · INPost Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute kidney injury (AKI) is common in the perioperative transplant period and is associated with poor outcomes. Few studies reported a reduction in AKI incidence with terlipressin therapy by counteracting the hemodynamic alterations occurring during liver transplantation. However, the effect of terlipressin on posttransplant outcomes has not been systematically reviewed. Methods: A comprehensive search of electronic databases was performed. Studies reporting the use of terlipressin in the perioperative period of living donor liver transplantation were included. We expressed the dichotomous outcomes as risk ratio (RR, 95% confidence interval [CI]) using the random effects model. The primary aim was to assess the posttransplant risk of AKI. The secondary aims were to assess the need for renal replacement therapy (RRT), vasopressors, effect on hemodynamics, blood loss during surgery, hospital and intensive care unit (ICU) stay, and in-hospital mortality. Results: A total of nine studies reporting 711 patients (309 patients in the terlipressin group and 402 in the control group) were included for analysis. Terlipressin was administered for a mean duration of 53.44 ± 28.61 h postsurgery. The risk of AKI was lower with terlipressin (0.6 [95% CI, 0.44-0.8]; Conclusions: Perioperative terlipressin therapy has no clinically relevant benefit.

Indexed as

acute kidney injuryAKI, acute kidney injuryBMI, body mass indexBUN, blood urea nitrogenC, controlCI, confidence intervalCNI, calcineurin inhibitorsCTP, Child-Turcotte-Pugh scoreDDLT, deceased donor liver transplantationGRWR, graft-torecipient weight ratioHCC, hepatocellular carcinomaHCV, hepatitis C virushemodynamicsHRS, hepatorenal syndromeICU, intensive care unitLDLT, living donor liver transplantationMAP, mean arterial pressureMELD, model for end-stage liver diseasemTORi, mammalian target of rapamycin inhibitorsNR, not reportedportal hypertensionPRBC, packed red blood cellsRCT, randomized controlled trialrenal replacement therapyRRT, renal replacement therapysCr, serum creatinineSD, standard deviationSVR, systemic vascular resistanceTp, Terlipressinvasoconstrictors

Identifiers

PMID35535072
PMCPMC9077193
OpenAlexW3176963304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.